Compare · DFTX vs PAVS
DFTX vs PAVS
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Paranovus Entertainment Technology Ltd. (PAVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and PAVS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 1323.8x PAVS ($4.5M).
- DFTX has been more active in the news (15 items in the past 4 weeks vs 2 for PAVS).
- DFTX has more recent analyst coverage (7 ratings vs 0 for PAVS).
- Company
- Definium Therapeutics Inc.
- Paranovus Entertainment Technology Ltd.
- Price
- -
- -
- Market cap
- $6.02B
- $4.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 15
- 2
- Recent ratings
- 7
- 0
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Latest PAVS
- SEC Form 20-F filed by Paranovus Entertainment Technology Ltd.
- SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.
- SEC Form NT 20-F filed by Paranovus Entertainment Technology Ltd.
- SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.
- Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split
- SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.
- SEC Form 424B5 filed by Paranovus Entertainment Technology Ltd.
- PAVS Announces Pricing of a $10 Million Registered Direct Offering of Class A Ordinary Shares and Pre-Funded Warrants
- Beyond Fast Fashion: Advanced Fibers and Smart Manufacturing Are Reshaping the Global Textile Industry
- SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.